US Stock MarketDetailed Quotes

SLS Sellas Life Sciences

Watchlist
  • 0.888
  • -0.010-1.11%
Close Dec 20 16:00 ET
  • 0.950
  • +0.062+6.98%
Post 19:50 ET
62.50MMarket Cap-1.33P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Dec 10 07:57
    NEWS
    $Sellas Life Sciences (SLS.US)$
    SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
    Tuesday, 10th December at 8:30 am
    -  Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis –
    -  REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 -
    -  Company to Host Webcast Call Today at 9:00 am ET
    NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: ...
    Trytosaveabit
    Trytosaveabit
    Dec 9 07:47
    Update
    $Sellas Life Sciences (SLS.US)$ SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
    2 MINUTES AGO, 8:45 AM EST
    VIA GLOBENEWSWIRE
    Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
    - Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Relat...
    Jaguar8
    Jaguar8
    Dec 9 07:45
    NEWS
    $Sellas Life Sciences (SLS.US)$
    SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
    Monday, 9th December at 8:45 am
    - Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
    - Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AM...
    Jaguar8
    Jaguar8
    Dec 8 16:31
    SLS presenting in ASH Conference
    $Sellas Life Sciences (SLS.US)$
    “SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses”
    Trytosaveabit
    Trytosaveabit
    Nov 27 07:50
    Update
    $Sellas Life Sciences (SLS.US)$ Reuters· 2 mins ago
    Sellas: Asxl1 Mutations Predictably Identified in Colorectal Cancer and Non-Small Cell Lung Cancer in Addition to Hematologic Malignancies
Read more
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
MicroStrategy
MSTR
+11.56%
Adobe
ADBE
+2.24%
Salesforce
CRM
+2.21%
Apple
AAPL
+1.88%
Meritage Homes
MTH
+1.78%

Unlock the Full List